SOUTH SAN FRANCISCO, Calif., June 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- Exelixis, Inc. (Nasdaq: EXEL) announces a webcast discussion of its clinical development financing strategy on Monday, June 13, 2005. The live webcast will be held at 5:30 a.m. PDT/8:30 a.m. EDT. To listen to the discussion, please visit the Webcast section under Investor Information on the Exelixis website at http://www.exelixis.com or http://www.vcall.com/CEPage.asp?ID=92376 .

An archive of this webcast will be available until 9:00 p.m. PDT/12:00 a.m. EDT on June 20, 2005. Access numbers for this replay are: 1-877-519-4471 (domestic) and 1-973-341-3080 (international); Conference ID number is: 6166620.

About Exelixis

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics across various disease areas. The company is leveraging its fully integrated gene-to- drug platform to fuel the growth of its proprietary drug pipeline. Exelixis' development pipeline covers cancer and metabolism and is comprised of the following compounds: XL119 (becatecarin), for which a multinational Phase III clinical trial has been initiated in patients with bile duct tumors; XL784, initially an anticancer compound, which completed a Phase I clinical trial and is being developed as a treatment for renal disease XL647, XL999 and XL880, anticancer compounds currently in Phase I clinical trials; XL820 and XL844 for which IND applications have been filed; and XL184, a potential IND candidate for the treatment of cancer; and multiple compounds in preclinical development for diseases including cancer and various metabolic and cardiovascular disorders. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies including GlaxoSmithKline (GSK) and Bristol-Myers Squibb Company. Pursuant to a product development and commercialization agreement between Exelixis and GSK, GSK has the option, after completion of Phase IIa clinical trials, to elect to develop a certain number of compounds in Exelixis' product pipeline, which may include the compounds identified in this press release (other than XL119), thus potentially triggering milestone payments and royalties from GSK and co- promotion rights by Exelixis. For more information, please visit the company's web site at http://www.exelixis.com .

SOURCE Exelixis, Inc.

Charles Butler, Associate Director of Corporate Communications for Exelixis, Inc.,
+1-650-837-7277, cbutler@exelixis.com

http://www.prnewswire.com